GLP-1 receptor agonists, already used for diabetes and obesity, show emerging potential to reduce intestinal inflammation in inflammatory bowel disease by strengthening the gut barrier and modifying the microbiome.
Dual-benefit potentialGLP-1 receptor agonists may address both the metabolic comorbidities (obesity, diabetes) and the intestinal inflammation in IBD patients, offering a unique dual-action therapeutic approach.
What the researchers found
GLP-1 receptor agonists appear to reduce the intestinal inflammatory burden through two main mechanisms: enhancing intestinal epithelial barrier function (the gut lining's ability to keep harmful substances out) and modulating the gut microbiota composition.
The review also addresses practical considerations including the safety profile of GLP-1 RAs in IBD patients, their impact on bowel preparation for endoscopic procedures (colonoscopies), and their effectiveness for managing the metabolic comorbidities (obesity, diabetes) that commonly accompany IBD. However, the evidence base consists primarily of preclinical studies and early clinical observations rather than definitive trials.
Why it matters
IBD affects millions of people worldwide and current treatments often have significant side effects or lose effectiveness over time. If GLP-1 drugs — which are already widely available and well-characterized for safety — could also help manage gut inflammation, this would represent a major advance. Many IBD patients also have obesity or diabetes, making GLP-1 RAs particularly attractive as they could potentially address multiple conditions simultaneously.
How the study worked
This is a narrative review that synthesized existing literature on GLP-1 biology, GLP-1 receptor agonist pharmacology, and their potential roles in inflammatory bowel disease. The review covered preclinical studies (animal and cell models) and early clinical observations, examining both the anti-inflammatory mechanisms and practical clinical considerations.
What this study cannot tell us
As a narrative review, the evidence selection may not be as systematic or unbiased as a formal systematic review. The supporting evidence comes primarily from preclinical studies and early clinical observations rather than randomized controlled trials. The review does not provide quantitative data on the magnitude of anti-inflammatory effects. Long-term safety of GLP-1 RAs specifically in IBD populations has not been established.
How to read the evidence
This is a narrative review synthesizing mostly preclinical research and early clinical observations. While it provides a useful overview of the emerging evidence, the lack of definitive clinical trials means the therapeutic potential remains speculative.
When this study was published
Published in 2025, this is a very current review capturing the latest thinking on GLP-1 RAs in IBD. The field is evolving rapidly as clinical interest in these drugs expands beyond metabolic diseases.
The bigger picture
GLP-1 receptor agonists continue to demonstrate effects far beyond their original diabetes indication. Their potential role in IBD adds to a growing list that includes cardiovascular protection, kidney disease, liver disease, and neurodegeneration. The gut-specific anti-inflammatory effects are particularly noteworthy because GLP-1 is naturally produced in the intestine, suggesting these drugs may be leveraging an endogenous protective pathway.
Questions still open
- Would GLP-1 receptor agonists be effective as add-on therapy to standard IBD treatments, or could they potentially replace some current immunosuppressive drugs?
- Do the gastrointestinal side effects of GLP-1 RAs (nausea, slowed gastric emptying) pose unique risks or complications for IBD patients?
- Which specific GLP-1 RA would be most appropriate for IBD given differences in gut-specific versus systemic effects across the drug class?
Common questions
Can GLP-1 drugs like semaglutide help with inflammatory bowel disease?
Why are researchers interested in GLP-1 drugs for IBD?
Read the original research
Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.
Current issues in molecular biology, 47(5)
Citation
Gravina, Antonietta Gerarda; Pellegrino, Raffaele; Izzo, Michele; De Costanzo, Ilaria; Imperio, Giuseppe; Landa, Fabio; Tambaro, Assunta; Federico, Alessandro. (2025). Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.. Current issues in molecular biology, 47(5). https://doi.org/10.3390/cimb47050383